Acuta Capital Partners’s PMV Pharmaceuticals PMVP Stock Holding History

Acuta Capital Partners’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100,000	Closed	-$2.08M	–	49
2022 Q1	$2.08M	Buy	+100,000	New	+$1.76M	0.97%	28

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acuta Capital Partners's PMVP Position: Q2 2023 in Review

Acuta Capital Partners sold out of PMV Pharmaceuticals (PMVP) in Q2 2023, closing a stake of 154,471 shares — an estimated $737K sold.

Acuta Capital Partners first reported a position in PMVP in Q4 2020 and held it in 7 quarters. The position peaked at $2.82M in Q1 2022. 106 funds tracked by Wall St. Rank hold PMVP as of Q2 2023.

Acuta Capital Partners reported no remaining PMV Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Acuta Capital Partners sold 154,471 PMV Pharmaceuticals shares in Q2 2023, an estimated $737K.
Acuta Capital Partners first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Acuta Capital Partners's PMV Pharmaceuticals position peaked at $2.82M in Q1 2022.
106 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2023.

Based on Acuta Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.